Stephanie Léouzon
Partner and Head of Torreya Europe
London Office | stephanie.leouzon@torreya.com | +44 (0) 207 451 4551
Stephanie Léouzon is Partner and Head of Torreya Europe. She has worked on over 100 strategic and financing transactions in the biopharmaceutical industry, with an aggregate value of over $75 billion.
Stephanie joined Torreya in 2011. Previously, she was a Managing Director and Senior Advisor at Credit Suisse in London. She has also worked at Salomon Brothers, as a Director of Healthcare Investment Banking, and as a Vice President in the Investment Banking divisions of JP Morgan, and Lehman Brothers in New York.
Highlights of Stephanie’s strategic advisory experience include the $34.6 billion Astra and Zeneca merger, the $6.8 billion Pharmacia & Upjohn merger, Hoechst’s $7 billion acquisition of Marion Merrell Dow; the creation of Syngenta through the merger of the agricultural businesses of AstraZeneca and Novartis; and the $3.1 billion Warner Chilcott LBO.
She has also led financings across several life sciences sectors, focusing on biotechnology and specialty pharma. She has worked on more than 15 Initial Public Offerings (IPOs) including Movetis, Warner Chilcott, Syngenta, GPC Biotech, Ark Therapeutics, Walsh International, IDEXX Labs, Viropharma, Pharmaceutical Marketing Services Inc., and Geron Corp. She has led Secondaries, Convertibles, Private Placements for, among many others, National Health Laboratories, Marion Merrell Dow, Oxford Glycosciences, BTG Therapeutics, Gilead Sciences, Skye Pharma, Centocor, Ark Therapeutics, American Medical Response, Pharmaceutical Marketing Services, Virco Holdings, and NaPro Biotherapeutics. A notable debt financing was the $2.4 billion bank and high yield financings for the LBO of Warner Chilcott.
Stephanie earned a B.A. cum laude from Mount Holyoke College and an M.A. and an M.B.A. from the Darden School at the University of Virginia.
She currently serves as a Non-Executive Director on the Board of BioPharma Credit PLC and also as a member of the Advisory Board for Great Ormond Street Hospital's Digital Research, Informatics and Virtual Environments (DRIVE) unit.
Selected Transactions
|
| Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC |
|
|
Up to $19 million
November 2018
|
|
| Licensing of ex European rights for LYS-SAF302 to |
|
|
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
|
|
| Licensing agreement for Feraccru® in Europe, Australia and New Zealand with |
|
|
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
|
|
| Company sale to |
|
|
> €75 million
November 2016
|
|
| License of milk allergy product to |
|
|
€100 million
May 2016
|
|
| Equity Financing Round |
|
|
|
€44.5 million
October 2020
|
|
| License of Navicixizumab to |
|
|
Up to $306 million
January 2020
|
|
|
| License of Feraccru® in China to |
|
|
$62.8 million
January 2020
|
|
| Sale of two orphan drug programs to |
|
|
Undisclosed
August 2019
|
|
| License of Nefecon in Greater China and Singapore to |
|
|
Up to $121 million
June 2019
|
|
|
| Acquisition of |
|
|
Up to $30 million
December 2015
|
|
| Acquisition of |
|
|
Up to €50 million
May 2015
|
|
| Financial advisor on IPO |
|
|
$30 million
October 2014
|
|
|
| Global offering advisory |
|
|
|
$133 million
October 2014
|
|
|
| Financial advisor in private placement |
|
|
|
€29.9 million
November 2013
|
|
| Sale of vaccine company to |
|
|
$250 million with
$35 million upfront May 2013
|
|
| Collaboration with |
|
|
|
Undisclosed
December 2012
|